Showing results (441-450 of 504) with videos related to

Sort By:
Pageof 51
Frontiers in Cardiovascular Medicine|December 15, 2015
Sex Differences in Correlates of Intermediate Phenotypes and Prevalent Cardiovascular Disease in the General PopulationRenate B Schnabel, Philipp S Wild, Jürgen H Prochaska, et al.
Clinical Research in Cardiology : Official Journal of the German Cardiac Society|February 10, 2023
Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus-results from the randomized, double-blind, placebo-controlled EmDia trialJürgen H Prochaska, Claus Jünger, Andreas Schulz, et al.
Journal of Thrombosis and Haemostasis : JTH|January 26, 2023
Severe high-molecular-weight kininogen deficiency: clinical characteristics, deficiency-causing KNG1 variants, and estimated prevalenceAnke Adenaeuer, Stefano Barco, Alice Trinchero, et al.
Clinical Kidney Journal|March 27, 2026
Increased albuminuria is highly prevalent in the general population: prevalence of CKD in the Gutenberg Health StudyDaniel Kraus, Alexander Gieswinkel, Simone Cosima Boedecker-Lips, et al.
Journal of Thrombosis and Haemostasis : JTH|July 9, 2021
Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19Anne Hollerbach, Nadine Müller-Calleja, Denise Pedrosa, et al.
Redox Biology|July 2, 2017
The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF ratsSebastian Steven, Matthias Oelze, Alina Hanf, et al.
Scientific Reports|July 6, 2017
Age-related diagnostic value of D-dimer testing and the role of inflammation in patients with suspected deep vein thrombosisJürgen H Prochaska, Bernd Frank, Markus Nagler, et al.
Thrombosis and Haemostasis|September 3, 2020
Relation between Tissue Factor Pathway Inhibitor Activity and Cardiovascular Risk Factors and Diseases in a Large Population SamplePauline C S van Paridon, Marina Panova-Noeva, Rene van Oerle, et al.
Pageof 51